Pfizer has agreed to acquire drugmaker Hospira for about $17 billion, a move that will likely precede more deals on behalf of the company, according to The Deal's Laura Cooper. Cooper explains how the deal will help Pfizer in its pursuit of new avenues for growth. Hospira is a big provider of injectable drugs and biosimilars, two areas that Pfizer describes as 'large and growing categories.' Pfizer estimates the global marketplace for injectables will grow to $70 billion by 2020 and the market for biosimilars to reach $20 billion globally by that time. Being as Pfizer lost out on a $120 billion deal with AstraZeneca last year, Cooper predicts we'll see the company stay on the path to finding more acquisitions in 2015.